Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
Subscribe To Our Newsletter & Stay Updated